Craig W. Lindsley, Ph.D.
William K. Warren, Jr. Chair in Medicine
Professor of Pharmacology and Chemistry
Director of Medicinal Chemistry
Director of The Vanderbilt Specialized Chemistry Center For Accelerated Probe Development
Editor of ACS Chemical Neuroscience
B.S. California State University at Chico, 1992
Ph.D. University of California at Santa Barbara, 1996
Phone: (615) 322-8700
Fax: (615) 343-6532
Location: 12415D MRB IV (Langford)
Craig Lindsley received his Ph.D. degree in chemistry in 1996 from the University of California, Santa Barbara, in the Lipshutz laboratory developing novel bi-directional organometallic linchpins for all-E polyene synthesis. Then as an ICCB (Institute of Chemistry and Cell Biology) postdoctoral fellow in the labs of Prof. Matt Shair at Harvard University, he developed a solid phase biomimetic synthesis of carpanone-like molecules.
After brief stints at Parke-Davis and Eli Lilly, Dr. Lindsley joined the Medicinal Chemistry Department at Merck and Company in West Point, PA. Merck where he established and led the Technology Enabled Synthesis (TES) group as a senior research fellow/group leader.
By application of an iterative parallel synthesis approach in combination with microwave synthesis technology and a custom, mass-directed preparative LCMS platform, Dr. Lindsley's TES group rapidly developed proof of concept compounds for nascent programs as well as four preclinical candidates with only 1-2 chemists/project. During his six years at Merck, Dr. Lindsley delivered six preclinical development candidates for cancer and neuroscience programs.
In 2006, Dr. Lindsley joined the faculty of the Vanderbilt University to direct the medicinal chemistry efforts of the Vanderbilt Center for Neuroscience Drug Discovery, with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. Dr. Lindsley is Associate Editor of Current Topics in Medicinal Chemistry and serves on the editorial boards of two other international journals. He serves on the Scientific Advisory Board of the NIH National Chemical Genomics Center, and is a worldwide medicinal chemistry consultant for Amgen. Dr. Lindsley's current research is focused on development of novel treatment strategies for schizophrenia, Parkinson's disease, and other brain disorders.